Our Mission
To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.
The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989
The U.S. Weight Loss Market: Status Report & 2026 Forecast
March 2026 108 Pages 27 tables/charts Price: $995
This new Marketdata report presents a wrap-up of 2025 performance for the U.S. weight loss market during the obesity drugs market explosion and a forecast for 2026. The value of the total market is estimated to have grown to a historic peak of $135 billion in 2025, boosted by soaring sales of the popular prescription GLP-1 weight loss drugs. This is a paradigm shift to medical programs, and a major challenge for competing commercial diet companies.
GLP-1 drugs are a game changer in terms of the number of medications now on the market, plus others to come in the next several years. They have affected dieter behavior and how commercial diet companies operate. Nearly all non-medical segments of the market have felt the pain of declining sales, and 26,000+ weight loss coaches have lost their jobs. However, more physicians are adding weight loss to their practices, the number of bariatricians are hitting new highs, and the number of medical weight loss centers has grown.
The report includes in-depth analyses of: 2024-2025 market/revenue performance, recent competitor and market developments, current dieter trends and top diet plans, and diet company advertising and marketing spending. Special emphasis and analysis of the obesity drugs market and its effect on all market segments. Coverage of cheaper compounded drugs that are not FDA-approved, new drugs entering the market.
Individual Status Reports and the effects of the obesity drugs boom on operations and revenues, for ALL major weight loss market segments… diet soft drinks, artificial sweeteners, health clubs industry, commercial weight loss chains, retail meal replacements and appetite suppressants, and low-calorie dinner entrees.
Medical programs covered in depth (MD programs, hospitals/clinic programs, prescription diet drugs, bariatricians, weight loss surgeries, very low calorie diet vendors).
Icludes profiles/updated outlooks/strategies/revenues for: Weight Watchers, NutriSystem, Jenny Craig, Medifast, Herbalife, Glanbia (Slim-Fast), Noom, Simply Good Foods (Dr. Atkins product line), HMR, Lindora, Beach Body, AMWAY, Bellring Brands (Premier Protein), Novo Nordisk, Eli Lilly.
Latest News
Herbalife Reports Q2 Results
June 30, 2026 Herbalife reported its Q2 results recently. The company sells a significant amount of weight management products in the United States and North America. In July 2026, Herbalife launched Bioniq, their next generation of personalized products, as well as new products within our Life I/O portfolio in North America, which includes a protein-based product and a ketone-based energy product. These launches are part of our ongoing efforts to provide innovative product offerings and support Member engagement. We will
Medifast Reports Q2 2026 Results
June 30, 2026 Management reported Medifast Q2 results, as follows: Second Quarter 2026 • Revenue: $76.4 million, with revenue per active earning coach of $6,529 • Independent active earning coaches of 11,700 • Net loss of $3.1 million or $0.28 loss per diluted share (“EPS”) • Cash, Cash Equivalents, and Investment Securities of $169.8 million with no debt Nick Johnson, Chief Executive Officer, commented, “In the second quarter, we continued to see signs of a turnaround in our business. Revenue
Medifast Launches Trilivy, Replaces Optavia
July 17, 2026 Medifast introduces a new program called Trilivy(TM), a science-backed metabolic health system. Trilivy replaces the former Optavia plan, that was focused only on weight loss. According to the press release: The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transformation, and the beginning of a
Weight Watchers Reports Q2 Results
August 5, 2026 WW reported its Q2 results today. Management said: “We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “Core+, our high-value Behavioral tier delivering tailored expert coaching and integrated weight health support, posted sequential subscriber growth for the third consecutive quarter, underscoring that members continue to
Marketdata weight loss reports have been quoted by..
